Radiation Oncologist at @DanaFarber @BrighamWomens @harvardmed and Research Fellow in @VanAllenLab. All views are my own.

Joined December 2009
2 Photos and videos
Excited to share our work on immune microenvironmental features in prostate cancer!
In our latest, a surprise - thanks to computational pathology - about immune cell clustering in prostate cancer and new ways to understand tumors, their neighborhoods, and clinical outcomes ... congrats @DYangMD et al! (link below)
7
1
14
2,531
Deeply grateful to my coauthors, the patients and loved ones who made this work possible, and @PCFnews for supporting this study 7/n
47
Together, our findings nominate immune spatial clustering as a potential biomarker of clinically meaningful immune enrichment in high-grade localized prostate cancer 6/n
49
These immune clusters were also associated with molecular features suggestive of a T cell-mediated antitumor response 5/n
41
We found that immune cell quantity alone was not associated with outcomes. Instead, a higher burden of spatially dense immune clusters was associated with a lower risk of distant metastasis in two independent cohorts 4/n
34
We leveraged deep learning analysis of H&E images (obtained as part of routine care) to evaluate whether immune features were associated with outcomes after prostatectomy 3/n
38
Growing evidence suggests that a subset of prostate cancer is immune-enriched, but the clinical consequences of immune enrichment were largely unknown 2/n
51
David Yang retweeted
11 Dec 2024
Tonight we sit with the cherished memories of a truly unforgettable individual who changed the lives of so many fighting cancer. Tomorrow we stand and get back to the fight against the terrible disease that took one of our best, brightest, and kindest. Love you forever, Felix.
11
26
162
30,062
3 Nov 2024
Excited to share work with coauthors Leslie Lee, @KatieLeeMDPhD @MtkingMD and others on "AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer." A tweetorial: 1/n
The volume of AI-segmented prostatic tumors was an independent prognostic factor for outcomes of localized prostate cancer treated with radical prostatectomy and radiation therapy. @BrighamRadOnc @DYangMD @KatieLeeMDPHD @MtkingMD bit.ly/4hnxfcw
8
2
15
1,570
3 Nov 2024
Many thanks to the coauthors and @PCFnews for the support 8/n
4
123
3 Nov 2024
If further validated, AI-determined tumor volume may become a novel biomarker for improving risk stratification for pts w/ localized PCa (in addition to genomics and computational pathology approaches) 7/n
3
127
3 Nov 2024
The AI-determined tumor volume may also have greater performance for predicting MFS than NCCN risk groups (e.g. AUROC for 7y MFS 0.84 vs 0.74, p=0.02 for RT-treated patients) 6/n
100
3 Nov 2024
Particularly interesting was our observation the intraprostatic tumor size was associated with both BCR and MFS for both RT and RP-treated patients, even after adjusting for the clinical, radiologic, and pathologic characteristics 5/n
88
3 Nov 2024
Using a cohort of 732 patients w/ PCa and mpMRIs, we built a segmentation model with the nnU-Net approach which showed good performance (e.g. F1 scores of 84-87% for PI-RADS 3-5 lesions across training/test cohorts) 4/n
110
David Yang retweeted
Hi folks - our lab in @DFCIPopSci has an opening for a post-doctoral fellow at the interface of prostate cancer and AI via collab. with Dr. Mary-Ellen Taplin @DanaFarber_GU - link below! careers.dana-farber.org/job/… @DanaFarber @broadinstitute @harvardmed

24
37
8,391
25 Oct 2023
Incredibly grateful for @PCF_Science for graciously supporting our work and @DrPaulNguyen @VanAllenLab and @MtkingMD for their wonderful mentorship!
🏆 Congratulations to @DYangMD on receiving the prestigious @PCFnews Young Investigator Award to work on Uncovering novel biomarkers in localized prostate cancer through radiomics and digital pathology! Mentors @VanAllenLab @DrPaulNguyen @MtkingMD pcf.org/c/young-investigator…
1
2
31
3,022